CHEMIBIONTICS Trademark

Trademark Overview


On Friday, June 30, 2023, a trademark application was filed for CHEMIBIONTICS with the United States Patent and Trademark Office. The USPTO has given the CHEMIBIONTICS trademark a serial number of 98066975. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Thursday, June 27, 2024. This trademark is owned by Empress Therapeutics, Inc.. The CHEMIBIONTICS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals; therapeutics; pharmaceutical preparations and therapeutic pharmaceuticals, both for the treatment of cancer, immune system-related diseases and disorders, endocrinological diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, and neurodegenerative diseases and disorders; pharmaceutical research and development; scientific and medical research and development; technical scientific consultation and product development for others in the field of biotechnology and the development of pharmaceuticals and microbial products; research and development in the field of computational biology, bioinformatics, genomics, biotechnology, pharmaceuticals, and microbial products; platform as a service (PAAS) featuring computer software platforms for research and development in the field of computational biology, bioinformatics, genomics, biotechnology, pharmaceuticals, and microbial products; drug discovery platform
chemibiontics

General Information


Serial Number98066975
Word MarkCHEMIBIONTICS
Filing DateFriday, June 30, 2023
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateThursday, June 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceuticals; therapeutics; pharmaceutical preparations and therapeutic pharmaceuticals, both for the treatment of cancer, immune system-related diseases and disorders, endocrinological diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, and neurodegenerative diseases and disorders; pharmaceutical research and development; scientific and medical research and development; technical scientific consultation and product development for others in the field of biotechnology and the development of pharmaceuticals and microbial products; research and development in the field of computational biology, bioinformatics, genomics, biotechnology, pharmaceuticals, and microbial products; platform as a service (PAAS) featuring computer software platforms for research and development in the field of computational biology, bioinformatics, genomics, biotechnology, pharmaceuticals, and microbial products; drug discovery platform

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 2, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEmpress Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events


Event DateEvent Description
Wednesday, August 2, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 14, 2024ASSIGNED TO EXAMINER
Thursday, June 27, 2024ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Thursday, June 27, 2024ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Friday, March 15, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 15, 2024NON-FINAL ACTION WRITTEN
Friday, March 15, 2024NON-FINAL ACTION E-MAILED